KHPG(SZ:002773) Xin Lang Cai Jing·2025-10-31 05:55Core Insights - Kanghong Pharmaceutical's stock increased by 5.09% to 34.05 CNY per share, with a trading volume of 320 million CNY and a turnover rate of 1.40%, resulting in a total market capitalization of 31.371 billion CNY [1] Company Overview - Chengdu Kanghong Pharmaceutical Group Co., Ltd. was established on October 3, 1996, and went public on June 26, 2015. The company is located at 108 Shuxi Road, Jinniu District, Chengdu, Sichuan Province [1] - The main business areas include research, production, and sales of chemical drugs, traditional Chinese medicine, and biological products [1] Revenue Composition - The revenue composition of Kanghong Pharmaceutical is as follows: - Biological drugs: 54.83% - Traditional Chinese medicine: 32.49% - Chemical drugs: 12.50% - Others: 0.15% - Additional (supplementary): 0.03% [1] Shareholder Insights - Dongzheng Asset Management has a fund that ranks among the top ten circulating shareholders of Kanghong Pharmaceutical. The fund, Oriental Red Medical Upgrade Stock Initiation A (015052), entered the top ten in the third quarter, holding 6.2959 million shares, which is 0.92% of the circulating shares [2] - The fund has achieved a return of 55.78% year-to-date, ranking 484 out of 4216 in its category, and a return of 55.04% over the past year, ranking 530 out of 3889 [2] Fund Performance - The Oriental Red Medical Upgrade Stock Initiation A (015052) fund increased its holdings in Kanghong Pharmaceutical by 149.88 thousand shares in the third quarter, making it the third-largest heavy stock in the fund, with 9.16% of the fund's net value [3] - The fund manager, Jiang Qi, has been in position for 3 years and 218 days, with a total fund asset size of 2.546 billion CNY and a best return of 47.81% during the tenure [2][3]